Intervention: Manganese(III)meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride
Trial phase: Phase 2
SMILES: CCN1C=CC=CC1=C1C2=NC(=C(c3cccc[n+]3CC)C3=NC(=C(c4cccc[n+]4CC)c4ccc([n-]4)C(c4cccc[n+]4CC)=C4C=CC1=N4)C=C3)C=C2.[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.

BMX-010 0.3%: Safety and efficacy of BMX-010 in topical treatment of acne.
Eligibility criteria:
Inclusion Criteria:

Male or female, at least 18 years of age;
A clinical diagnosis of mild to severe facial Acne Vulgaris; Subjects may also have acne at other body sites;
Screening and Baseline IGA score > 2 (greater than or equal to 2);
Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
Candidate for topical treatment of Acne;
If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup.
Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
Ability to understand and provide written informed consent.

Exclusion Criteria:

Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
Use of androgen receptor blockers (such as spironolactone or flutamide);
Severe cystic acne, acne conglobate, acne fulminans, or secondary acne;
Use of phototherapy devices, energy-based devices, adhesive cleansing strips, or cosmetic procedures (e.g., facials, peeling, comedo extraction) in the past week;
Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
Prior or current concomitant therapies that would interfere with assessments in the study;
Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products [e.g., benzamycin]), retinoids; other topical acne treatments (e.g., photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks;
Oral retinoid use (e.g., isotretinoin) within 6 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline;
Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
Use of medicated make-up (including anti-aging make-up) throughout the study;
Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact acne, 4) immunosuppressive agents, or immunomodulators;
Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical acne treatments or 4) topical antibiotics;
Use of medicated cleansers on the face (throughout the study);
Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
Systemic or skin infection requiring antimicrobial therapy;
Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
Active drug or alcohol dependence;
Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
Previous clinical trial participation for the indication being treated in this protocol.